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6/j.bThe optimal pretransplant regimen for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
in patients $55 years of age remains to be determined. The myeloablative reduced-toxicity 4-day regimen
i.v. busulfan (Bu) (130 mg/m2) and i.v. fludarabine (Flu) (40 mg/m2) is associated with low morbidity and mor-
tality. We analyzed 79 patients $55 years of age (median, 58 years) with AML (n 5 63) or MDS (n 5 16)
treated with i.v. Bu-Flu conditioning regimens between 2001 and 2009 (median follow-up, 24 months). The
patients who received this regimen had a good performance status. The 2-year overall survival (OS) rates for
patients in first complete remission (CR1), second CR (CR2), or refractory disease and for all patients at
time of transplantation were 71%, 44%, 32%, and 46%, respectively; 2-year event-free survival (EFS) rates
for patients in CR1, CR2, or refractory disease at time of transplantation and for all patients were 68%,
42%, 30%, and 44%, respectively. One-year transplant-related mortality (TRM) rates for patients who
were in CR or who had active disease at the time of transplantation were 19% and 20%, respectively. Grade
II-IV acute graft-versus-host (aGVHD) disease was diagnosed in 40% of the patients. Our results suggest that
age alone should not be the primary reason for exclusion from receiving myeloablative reduced-toxicity
conditioning with i.v. Bu-Flu preceding transplantation in patients with AML/MDS.
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Acute myeloid leukemia (AML) is primarily a dis-
ease of the elderly, with amedian patient age at diagno-
sis of 70 years [1]. AML is an aggressive disease, with
AML patients having a 5-year relative survival rate of
5% to 15%. Patient-, disease-, and donor-related is-
sues limit and, at times, exclude the use of allogeneic
hematopoietic stem cell transplantation (allo-SCT),
which can be curative. Many factors contribute to
the adverse outcomes of allo-SCT in elderly patients
with AML [2-4]. First, age-associated comorbid
conditions impact the tolerance to chemotherapy.
Second, many pharmaceutically active agents are
metabolized differently in older individuals [5,6], and
total systemic exposure of the conditioning therapy
is not only related to overall toxicity, but also to
acute graft-versus-host disease (aGVHD), presumably
through cytokine release from damaged organs [7].
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higher incidence of GVHD is partly because of an al-
tered immune response, such as enhanced allogeneic
stimulatory activities of antigen-presenting cells [8].
Fourth, the potential of T cells to mediate antileuke-
mia activities is reduced in elderly patients, thereby
limiting the beneficial graft-versus-leukemia effect.
Additionally, the diversity in the naive T cell repertoire
is decreased after the seventh decade of life; this defi-
ciency is compounded by a reduced ability of the thy-
mus to rebuild a broad T cell repertoire to target
a wide range of antigens [9]. Finally, stem cell homing,
and therefore engraftment, may also be adversely af-
fected by aging [10]. These deficiencies underscore
the critical need for a regimen that will maximize the
eradication of residual leukemia cells and allow
prompt engraftment with rapid reconstitution of
immune response to mediate optimal antileukemia
immunity.
Effective cytoreduction is critical in the treatment
of elderly patients with AML, as it reduces the disease
burden, and permits rapid engraftment and immune
reconstitution with long-term disease control. If an ab-
lative regimen can be safely delivered to patients up to
and beyond 65 years of age, the currently held notion
that reduced-intensity conditioning (RIC) is the opti-
mal approach in this age group would be challenged.
Paradoxically, from the antileukemia standpoint, and
also in consideration of the immunologic challenges
imposed by aging, an optimally cytoreductive, myeloa-
blative conditioning regimen may be even more desir-
able in older patients.
The reduced-toxicity intravenous (i.v.) busulfan
(Bu)-fludarabine (Flu) regimen was shown to be
a safe myeloablative conditioning program when com-
pared with the more commonly used regimen of Bu-
cyclophosphamide (Cy) in the treatment of patients
with AML [11]. In that study, the outcome of 67 pa-
tients who received the Bu-Cy regimenwere compared
with 148 patients who received the Bu-Flu condition-
ing regimen prior to allo-SCT for AML; patients
whose disease was in first complete remission (CR1)
who received Bu-Flu had significantly better 3-year
overall survival (OS) and event-free survival (EFS)
rates than those who received Bu-Cy, despite the
higher median age of the Bu-Flu population (46 versus
39 years) [11]. Of importance, the 3-year treatment-
related mortality, which is often attributed to the con-
ditioning regimen’s toxicities, was significantly lower
in the Bu-Flu group (14% versus 34%). In our early
study [11], we had transplanted some patients who
were in the 7th decade of life using the Bu-Flu regi-
men, and our impression was that the results would
support the use of i.v. Bu-Flu in ‘‘elderly patients’’—
in this report defined as being older than 50 to 55 years
of age. Based on the success of Bu-Flu in this age
bracket, we hypothesized that i.v. Bu-Flu might bea safe and effective conditioning therapy in elderly pa-
tients prior to allo-SCT for AML and myelodysplastic
syndrome (MDS).
In view of this hypothesis, we retrospective ana-
lyzed 79 patients treated with the reduced-toxicity
myeloablative regimen i.v. Bu-Flu.We critically exam-
ined the use of i.v. Bu-Flu followed by allo-SCT for
AML and MDS patients in the 6th to 8th decades of
life, and the present paper describes details of this in-
vestigation. Our data support the systematic use of
the i.v. Bu-Flu conditioning regimen in high-risk
patients older than 50 to 55 years, if they have
a good performance status.MATERIALS AND METHODS
Patients
We studied all patients 55 years or older who had
been treated in 2 consecutive prospective protocols con-
ducted at our institution (TheUniversity of TexasM.D.
AndersonCancerCenter) and 5 patients treatedwith the
same regimen in aprospective clinical trial atHospital Is-
raelita Albert Einstein (Sao Paulo, Brazil). The first pro-
tocol was a phase II study that investigated high-dose i.v.
Bu-Fluwith fixed-dose delivery [12], whereas the second
protocol compared a regimen of i.v. Bu-Flu with fixed-
dose Bu with a regimen containing dose-adjusted Bu in
which pharmacokinetic monitoring targeted a systemic
exposure of Bu as represented by the average daily area
under the concentration versus time curve for Bu of
6000 mMol$min for each of the 4 days of the regimen,
similar to previous reports [13,14]. The studies were
approved by institutional review board, and all patients
provided written informed consent as per institutional
guidelines. The i.v. busulfan was purchased from
Otsuka America Pharmaceutical, Inc. (Princeton, NJ).
To be eligible for these studies, patients were re-
quired to have adequate normal organ functions:
hepatic function (SGPT # 200 IU/mL, serum biliru-
bin, and alkaline phosphatase within accepted labora-
tory standard normal limits or considered not
clinically significant, and no evidence of chronic active
hepatitis or cirrhosis); renal function (serum creatinine
#1.5 mg/dL); cardiac function (left ventricular ejec-
tion fraction .45%; no uncontrolled arrhythmias or
symptomatic cardiac disease); and pulmonary function
(no symptomatic pulmonary disease, and FEV1, FVC,
and DLCO $50% of expected corrected for hemo-
globin). AML patients were required to have disease
status past first remission, primary induction failure,
in first or subsequent relapse, or in first remission
with intermediate- or high-risk cytogenetics; MDS
with intermediate- or high-risk International Prog-
nostic Scoring System score; no systemic therapy ad-
ministered within 21 days prior to trial enrollment;
no active infection; and Zubrod performance status
Table 1. Pretransplant Patient Characteristics
Characteristic Number (%)
Gender
Male 49 (62)
Female 30 (38)
Age
>58 40 (51)
#58 39 (49)
Disease
AML 63 (80)
MDS 16 (20)
Disease status at time of allo-SCT
CR 42 (53)
CR1 25 (32)
CR2 17 (22)
Active disease 37 (47)
Cytogenetics
Good risk 4 (5)
Intermediate risk 50 (63)
Poor risk 20 (25)
Unknown 5 (6)
Graft received
Related Donor 41 (52)
Unrelated Donor 38 (48)
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translocation (t)(8;21); inversion (inv)(16) or t(16;16);
deletion (del)(9q); or t(15;17). Intermediate-risk cyto-
genetics included patient with a normal karyotype;
2Y; del (5q); loss of 7q; t(9;11); 111; del(11q); abnor-
mality (12p); 113; del(20q); or 121. High-risk cyto-
genetics included patients with a complex karyotype
($3 abnormalities); inv(3) or t(3;3); t(6;9); t(6;11);
27; 18 (sole abnormality); or 18 with 1 other abnor-
mality other than t(8;21), t(9;11), inv(16), or t(16;16);
t(11;19)(q23;p13.1) [15].
The conditioning regimen consisted of i.v. Flu (40
mg/m2) (Genzyme Inc., Cambridge, MA) and i.v. Bu
(130 mg/m2) administered over a 3-hour period once
a day on pretransplant days26 to23 [12]. Tacrolimus
and minimethotrexate were used for GVHD prophy-
laxis [16], and pentostatin (Hospira Inc., Lake Forest,
IL) was administered in 13 cases (18%). Thymoglobu-
lin (4 mg/kg) (Genzyme Inc., Cambridge, MA) was ad-
ministered to those who received grafts from
mismatched related or unrelated donors on days 23
to 21. All donor-recipient pairs were fully typed at
high resolution for the alleles of HLA-A, -B, -C,
-DR, and -DQ.
Statistical Analysis
The primary outcomes of interest in the current
analysis were OS and EFS rates, cumulative incidence
of transplant-relatedmortality (TRM), and cumulative
incidence of aGVHD. All outcomes were evaluated
from the date of transplantation, with the exception
of monitoring for regimen-related adverse events,
which included the days of chemotherapy administra-
tion. The probabilities of survival were estimated using
the Kaplan-Meier method [17,18]. The log-rank test
was used to compare survival probabilities between
subgroups of patients. The cumulative incidence of
TRM was estimated by considering death because of
disease relapse and/or resistance or any other
nontreatment-related cause as a competing risk. The
cumulative incidence of aGVHD was estimated by
considering disease progression or death because of
any cause as a competing risk. All statistical analyses
were performed using SAS and S-plus software (SAS
Institute Inc., Cary, NC). P values\.05 were deemed
statistically significant [17,18].Stem cell source
Bone marrow 38 (48)
Peripheral blood 41 (52)
HCT-CI Score*
#1 41 (52)
2 9 (11)
$3 27 (34)
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome;
allo-SCT, allogeneic stem cell transplantation; CR, complete remission;
CR1, first complete remission; CR2, second complete remission; HCT-CI,
hematopoietic stem cell transplantation comorbidity index [19].
Percentages listed are of the total number of patients (n 5 79).
*Data were unavailable for 2 patients.RESULTS
Patients
Seventy-nine patients 55 years or older with either
AML (n 5 63; secondary AML [n 5 8]) or MDS (n 5
16) underwent allo-SCT from September 2001 to
May 2009. Pretransplant patient characteristics are
presented in Table 1. The median age at the time of
transplantation was 58 years (range: 55-76 years);5 patients were older than 65. The median survival
was 8 months (range: 1-82 months). Eighty percent
(n5 20) and 16% (n5 4) of patients in CR1 had inter-
mediate- and poor-risk cytogenetics, respectively, and
cytogenetics were unknown in 1 patient. Six percent
(n51), 82%(n514), and6%(n51) of patients inCR2
had good-, intermediate-, and poor-risk cytogenetics,
respectively; cytogenetics were unknown in 1 patient.
The median hematopoietic stem cell transplantation
comorbidity index (HCT-CI) score was 1 [19].
OS and EFS
The2-yearOSandEFSrates for the25patientswho
underwent transplantation while in CR1 were 71% and
68%, respectively (Table 2 and Figure 1A-B). The
2-year OS and EFS rates for the entire cohort were
46% and 44%, respectively (Figure 1C-D). The 17 pa-
tientswhounderwent transplantationwhile their disease
was in second complete remission (CR2) had 44% 2-
yearOS ratewhile the 37patientswho had active disease
at the timeof allo-SCThad32%2-yearOSrate.Thirty-
twopercent of patients haddisease progression (n5 25).
Disease status was the strongest predictor of OS time
(P 5 .006), with patients in CR1 having the longest
OS time, followedby those inCR2 and thosewith active
disease at time of transplantation.
Table 2. Posttransplant Outcomes
Characteristic Number (%)
GVHD
Acute, grade II-IV 32 (41)
Acute, grade III-IV 5 (7)
Chronic 34 (43)
Cause of death*
Disease progression 23 (58)
GVHD 9 (23)
Infection 4 (10)
Organ failure 3 (8)
Kaplan-Meier estimate (95% CI)
2-year OS†
CR1 71% (54%-94%)
CR2 44% (24%-81%)
Active disease 32% (19%-53%)
2-year EFS†
CR1 68% (51%-91%)
CR2 42% (23%-77%)
Active disease 30% (18%-50%)
GVHD indicates graft-versus-host disease; OS, overall survival; CR1,
first complete remission; CR2, second complete remission; EFS,
event-free survival.
Except as noted, all percentages are calculated for the entire cohort
(n 5 79).
*Percentages reported in each cause-of-death category were calculated
from the total number of patients who died (n 5 40).
†Percentages reported for 2-year OS and EFS were categorized by dis-
ease status at the time of allo-SCT.
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Posttransplant outcomes are reported in Table 2.
Engraftment was achieved in all patients. At day
130, 73% of patients (n5 56) had achieved full donor
chimerism and 23% (n 5 18) mixed chimerism
(defined as the presence of any recipient cell or DNA
as detected by cytogenetics, fluorescence in situ hy-
bridization, or DNA microsatellite polymorphisms);Figure 1. Kaplan-Meier curves for OS and EFS. OS and EFS probabilities forchimerism data were unavailable for 5 patients. Over-
all, 100-day mortality was 6% (n 5 5) and was caused
by secondary graft failure (n 5 1), persistence of
disease (n 5 1), liver failure (n 5 1), central nervous
system (CNS) bleed (n 5 1), and preexisting
radiation-induced brain toxicity (n 5 1). Forty-one
percent of patients (n 5 32) developed grade II-IV
aGVHD, 7% (n5 5) developed grade III-IV aGVHD,
and 43% (n 5 34) developed chronic GVHD
(cGVHD). The cumulative incidence of aGVHD
(grades II-IV) is shown in Figure 2. Our analysis also
showed that the HCT-CI score was higher (median
score, 2) in patients with grade II-IV aGVHD,
compared with patients who had aGVHD grades 0-1
(median score, 1) (P 5 .02).
TRM was 1% at day 130 for all patients, and was
highest in patients who underwent stem cell transplan-
tation with active disease. TRM rates at day 1100 for
patientswhounderwent stem cell transplantationwhile
in CR and for patients with active disease at time of
stem cell transplantation were 5% for both groups.
One-year TRM rates for patients who were in CR or
who had active disease at the time of stem cell trans-
plantation were 19% and 20%, respectively (Table 3).
Effects of Age on OS
We further investigated whether age at the time of
allo-SCT affected OS rates. For this analysis, we allo-
cated the patients into 2 groups using the median age
of 58 years as the cutoff (ie,\58 versus $58 years).
Our results showed that OS was not significantly
affected by age (median follow-up, 24 months)
(Figure 3). Our data also showed that age alone did
not affect outcome, regardless of disease status at the
time of transplantation (Figure 4).(A-B) patients in CR1 (n 5 25) and (C-D) for entire cohort (n 5 79).
Figure 2. Cumulative incidence of grade II-IV acute graft-versus-host
disease.
Figure 3. Overall survival in patients 58 years or older versus patients
younger than 58 years.
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In this analysis of 79 patients with AML or MDS
who were $55 years of age at time of allo-SCT, we
showed good outcomes, including OS, EFS, TRM,
and GVHD rates, following the use of the myeloabla-
tive, reduced-toxicity i.v. Bu-Flu regimen. Because it
remains unknown whether there should be an optimal
age to use for excluding patients from allo-SCT or
from receiving this type of myeloablative regimens,
and because many older adults with AML or MDS
are offered RIC regimens prior to allo-SCT purely be-
cause of their age, our results challenge the current
treatment tradition of offering mostly reduced-
intensity programs for older patients with AML and
MDS. Furthermore, our findings are especially impor-
tant because AML andMDS are of intermediate sensi-
tivity to the graft-versus-leukemia effect, and higher
doses of chemotherapeutic agents are often required
for effective disease control [20,21]. Therefore, we
show that selected patients $55 years of age with
AML or MDS can be safely treated with the reduced-
toxicity i.v. Bu-Flu regimen, with acceptable overall
outcomes and encouraging long-term disease control.
Our results are consistent with our prior report
that employed i.v. Bu-Flu as a conditioning regimen
for allo-SCT in a cohort of patients with a medianTable 3. Transplant-Related Mortality
Transplant-Related
Mortality 30 days 100 days 1 year 3 year
All patients (n 5 79) 1% 5% 19% 26%
All CR at allo-SCT (n 5 42) None 5% 19% 26%
CR1 at allo-SCT (n 5 25) None 4% 14% 19%
Active disease (n 5 37) 3% 5% 20% 27%
CR indicates complete remission; allo-SCT, allogeneic stem cell trans-
plantation; CR1, first complete remission.
Percentages shown are calculated based on the total number of patients
in each category.age of 46 years [11,12]. The 2-year OS and EFS rates
we observed here for patients whose disease was in
CR1 were 71% and 68%, respectively; these rates
were similar to the OS and EFS rates (78% and
74%, respectively) that we previously reported using
this myeloablative i.v. Bu-Flu regimen [11,12].
Additionally, our outcomes compare favorably to
RIC i.v. Bu-Flu [22,23], which in older ($60 years,
median age, 63 years) leukemia patients (62% with
AML or MDS) was shown to have 2-year cumulative
incidence of nonrelapse mortality (NRM) and OS of
10% and 46%, respectively [22].
It has lately become a practice to exclude older
AML or MDS patients from myeloablative condition-
ing regimens. This is unfortunate, knowing that, in
comparison with RIC regimens, a more potent disease
eradication may yield a distinct benefit in patients. In
one study, elderly patients (median age, 64 years)
treated with the RIC regimens consisting of Flu, mel-
phalan, and carmustine followed by allo-SCT achieved
1-year OS, disease-free survival (DFS), andNRM rates
of 68%, 61%, and 22%, respectively [24]. Another
study in older patients (median age, 53 years) using
a nonmyeloablative conditioning regimen with i.v.
Flu and oral Bu showed 4-year OS and EFS and 1-
year NRM rates of 42%, 44%, and 16%, respectively
[25]. We have previously reported 3-year OS and
EFS and 1-year NRM rates of approximately 40%,
20%, and 20%, respectively, in older patients (average
age, 61 years) who received the nonmyeloablative reg-
imen Flu, cytarabine, and idarubicin [20].
Previous studies using myeloablative conditioning
regimens prior to allo-SCT in elderly patients have re-
ported poor outcomes secondary to high NRM rates.
Wallen et al. [26] evaluated ablative allo-SCT in adults
60 years or older (median age, 63 years); most patients
received Bu-Cy (67%) or total body irradiation (TBI)-
Cy (21%), and only 10% of the patients received Bu-
Flu; 3-year OS and relapse rates were estimated to be
34% and 24%, respectively; 100-day and 3-year
Figure 4. Kaplan-Meier curve for OS according to remission status at
time of transplantation. (A) OS in patients 58 years or older versus pa-
tients younger than 58 years who underwent transplantation while their
disease was in complete remission. (B) OS in patients 58 years or older
versus patients younger than 58 years who underwent transplantation
while they had active disease.
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43%, respectively; and the aGVHD (grade III-IV)
rate was 20% (versus 7% in our study). In a subgroup
analysis of older patients with AML who received un-
related donor grafts preceded by RIC or myeloablative
conditioning regimens, Ringden et al. [27] showed that
patients 50 years or older (median age, 54 years) who
received myeloablative conditioning regimens had 2-
year leukemia-free survival, NRM, and aGVHD
(grade II-IV) rates of 43%, 39%, and 29%, respec-
tively. However, similar to the study by Wallen et al.
[26], in the report by Ringden et al. [27], only 14%
of patients 50 years or older received Bu-Flu, whereas
the majority of patients received either TBI-Cy (47%)
or Bu-Cy (34%).
Cahn et al. [28] retrospectively compared allo-
SCT in AML patients over 40 years old to those age
40 and younger who underwent transplantation while
their disease was in CR1 and reported similar relapse
incidence andOS rates between the 2 groups; however,
the rate of TRM was higher in patients older than 40
years, and most of these patients received Cy-TBI orBu-Cy as their conditioning regimens. Likewise, in
an analysis of 71 patients with de novo MDS who re-
ceived Cy-TBI or Bu-Cy conditioning regimens,
Sutton et al. [29] reported shorter OS and EFS times
and a higher relapse rate among patients who under-
went transplantation at a later age (median, 37 years).
We recognize the plethora of data that support RIC
regimens in older AML and MDS patients, but when
contrasted with these previous studies, our results
highlight the need to reevaluate age as an exclusion
criterion for myeloablative regimens in light of the
improved outcomes with i.v. Bu-Flu.
Recently, studies of patients 50 years or older with
AML or MDS were conducted by the European
Group for Blood and Marrow Transplantation and
showed increased disease relapse rates following RIC
compared with myeloablative conditioning regimens;
in essence, the increase in disease relapse for RIC off-
sets the increase in TRM for the myeloablative regi-
mens [27]. Our analysis does not compare current
data with historical controls, and in the absence of ran-
domized trials, the issue of dose intensity remains
unresolved. However, our findings suggest that older
patients can benefit from the reduced-toxicity, mye-
loablative i.v. Bu-Flu regimen, which we showed likely
to be less toxic and significantly safer than other com-
monly used myeloablative regimens. It is assumed that
providing optimized cytoreduction contributes to
improved long-term disease control [20,30].
In view of our results, we recommend that the
reduced-toxicity i.v. Bu-Flu regimen be considered
for patients up to at least age 65, unless they suffer seri-
ous comorbid conditions. The tolerance for this ther-
apy in elderly patients with serious comorbidities has
not been evaluated under stringent, well-controlled
conditions, and such patients may benefit from addi-
tional precautions. The regimen, however, could be
considered for selected patients with comorbid condi-
tions in this age group, if the treatment is given in a con-
trolled clinical study to evaluate the tolerance to
administered treatment in such a setting. As previously
demonstrated in younger patients, the regimen seems
especially fit for patients whose disease is in CR
[11,12]. For patients whose disease is not in CR at the
time of allo-SCT, to date, no regimen has been identi-
fied as the ‘‘standard conditioning regimen,’’ and a vari-
ety of approaches are under investigation, including the
replacement or supplementation of fludarabine with
clofarabine [31] complementation of i.v. Bu-Flu with
low-dose TBI [32] and/or post-allo-SCTmaintenance
therapy to prolong CR in high-risk patients [33,34].ACKNOWLEDGMENTS
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